Stock 49B BEIGENE, LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Company BeiGene, Ltd. Deutsche Boerse AG

Equities

49B

KYG1146Y1017

Biotechnology & Medical Research

Market Closed - Deutsche Boerse AG
Other stock markets
 02:20:01 2024-04-18 am EDT 		5-day change 1st Jan Change
9.35 EUR -0.53% Intraday chart for BeiGene, Ltd. -9.22% -24.60%
Apr. 17 BeiGene to Award Shares Worth $15 Million to 11 Directors MT
Apr. 11 Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech MT

Business Summary

BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.

Number of employees: 10,600

Sales per Business

USD in Million2022Weight2023Weight Delta
Pharmaceutical Products
100.0 %
1,416 100.0 % 2,459 100.0 % +73.65%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
45.9 %
503 35.5 % 1,128 45.9 % +124.46%
China
44.8 %
840 59.3 % 1,102 44.8 % +31.18%
Europe
8.2 %
-- 202 8.2 % -
Rest of World
1.1 %
73 5.2 % 27 1.1 % -63.70%

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 1,244,457,968 1,222,239,074 ( 98.21 %) 0 98.21 %

Shareholders

NameEquities%Valuation
AMGEN INC.
19.82 %
246,269,426 19.82 % 2 992 M €
Capital Research & Management Co. (International Investors)
8.324 %
103,421,157 8.324 % 1 257 M €
HHLR Advisors Ltd.
6.084 %
75,588,463 6.084 % 918 M €
John Oyler
6.020 %
74,797,345 6.020 % 909 M €
Xiao Dong Wang
1.649 %
20,486,365 1.649 % 249 M €
Capital International, Inc.
0.8900 %
11,057,735 0.8900 % 134 M €
Donald Glazer
0.2502 %
3,108,659 0.2502 % 38 M €
Capital International SARL
0.2047 %
2,543,315 0.2047 % 31 M €
Invesco Great Wall Fund Management Co. Ltd. (Invt Mgmt)
0.1672 %
2,078,000 0.1672 % 25 M €
Lai Wang
0.1335 %
1,658,215 0.1335 % 20 M €
NameEquities%Valuation
Taiping Life Insurance Co. Ltd. (Investment Portfolio)
2.092 %
2,407,263 2.092 % 44 M €
Abu Dhabi Investment Authority (Investment Management)
2.092 %
2,407,263 2.092 % 44 M €
China International Capital Corp. Ltd. (Invt Management)
1.799 %
2,069,546 1.799 % 38 M €
Guangxi Tongfu Kexing Investment Management LP
1.255 %
1,444,358 1.255 % 26 M €
Shanghai State-Owned Assets Supervision & Administration
1.255 %
1,444,358 1.255 % 26 M €
Eurizon Capital Asia Ltd.
0.1072 %
123,369 0.1072 % 2 M €
State Street Global Advisors Ltd.
0.005128 %
5,900 0.005128 % 107 919 €
Bank of Beijing Scotiabank Asset Management Co., Ltd.
0.003967 %
4,564 0.003967 % 83 482 €
Manulife TEDA Fund Management Co., Ltd.
0.003340 %
3,843 0.003340 % 70 294 €
Rongtong Fund Management Co., Ltd.
0.003132 %
3,603 0.003132 % 65 904 €
NameEquities%Valuation
Baker Bros. Advisors LP
11.06 %
10,568,897 11.06 % 1 653 M €
Capital Research & Management Co. (International Investors)
6.630 %
6,336,872 6.630 % 991 M €
HHLR Advisors Ltd. (Cayman Islands)
5.416 %
5,176,906 5.416 % 810 M €
PRIMECAP Management Co.
5.219 %
4,988,639 5.219 % 780 M €
Baillie Gifford & Co.
4.045 %
3,866,449 4.045 % 605 M €
Temasek Holdings Pte Ltd.
3.154 %
3,014,171 3.154 % 471 M €
T. Rowe Price International Ltd.
1.996 %
1,908,189 1.996 % 298 M €
Fidelity Management & Research Co. LLC
1.801 %
1,721,303 1.801 % 269 M €
Capital International, Inc.
0.8472 %
809,749 0.8472 % 127 M €
BlackRock Advisors LLC
0.7865 %
751,710 0.7865 % 118 M €

Holdings

NameEquities%Valuation
LEAP THERAPEUTICS, INC.
2.87%
 734,844 2.87% 1,954,685 $

Company contact information

BeiGene Ltd.

94 Solaris Avenue Camana Bay

KY1-1108, George Town

+345 949 4123

http://www.beigene.com
address BeiGene, Ltd.(49B)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per region

Ratings for BeiGene, Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
131.9 USD
Average target price
268.6 USD
Spread / Average Target
+103.73%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-3.30% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.79% 96.84B
ARGENX SE Stock argenx SE
-0.44% 21.48B
BIONTECH SE Stock BioNTech SE
-18.35% 20.82B
GENMAB A/S Stock Genmab A/S
-7.45% 18.6B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-40.31% 16.81B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+0.59% 13.4B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+20.86% 11.06B
LEGEND BIOTECH CORPORATION Stock Legend Biotech Corporation
-21.69% 8.88B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. BGNE Stock
  4. 49B Stock
  5. Company BeiGene, Ltd.